Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
July 13, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
June 29, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase...
Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact
June 01, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final...
Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference
April 25, 2023 07:35 ET
|
Reunion Neuroscience Inc.
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
April 25, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors
April 03, 2023 07:30 ET
|
Reunion Neuroscience Inc.
- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and...
Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
March 27, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Files Lawsuit Against Mindset Pharma
March 13, 2023 18:52 ET
|
Reunion Neuroscience Inc.
TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
March 07, 2023 07:30 ET
|
Reunion Neuroscience Inc.
TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
February 14, 2023 07:30 ET
|
Reunion Neuroscience Inc.
Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to...